Impact of number of nodes retrieved on outcome in patients with rectal cancer

被引:449
作者
Tepper, JE
O'Connell, MJ
Niedzwiecki, D
Hollis, D
Compton, C
Benson, AB
Cummings, B
Gunderson, L
Macdonald, JS
Mayer, RJ
机构
[1] Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA
[2] Duke Univ, Med Ctr, Canc & Leukemia Grp B, Stat Off, Durham, NC USA
[3] Mayo Clin, Ctr Canc, Rochester, MN USA
[4] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA
[5] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[6] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA USA
[7] Northwestern Univ, Div Hematol Oncol, Chicago, IL USA
[8] Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON M4X 1K9, Canada
[9] St Vincents Clin, Ctr Canc, Gastrointestinal Oncol Serv, New York, NY USA
关键词
D O I
10.1200/JCO.2001.19.1.157
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We postulated that the pathologic evaluation of the lymph nodes of surgical specimens from patients with rectal cancer can have a substantial impact on time to relapse and survival. Patients and Methods: We analyzed data from 1,664 patients with T3, T4, or node-positive rectal cancer treated in a national intergroup trial of adjuvant therapy with chemotherapy and radiation therapy. Associations between the number of lymph nodes found by the pathologist in the surgical specimen and the time to relapse and survival outcomes were investigated. Results: Patients were divided into groups by nodal status and the corresponding quartiles of numbers of nodes examined. The number of nodes examined was significantly associated with time to relapse and survival among patients who were node-negative. For the first through fourth quartiles, the 5-year relapse rates were 0.37, 0.34, 0.26, and 0.19 (P = .003), and the 5-year survival rates were 0.68, 0.73, 0.72, and 0.82 (P = .02). No significant differences were found by quartiles among patients determined to be node-positive. We propose that observed differences are primarily related to the incorrect determination of nodal status in node-negative patients. Approximately 14 nodes need to be studied to define nodal status accurately. Conclusion: These results suggest that the pathologic assessment of lymph nodes in surgical specimens is often inaccurate and that examining greater number of nodes increases the likelihood of proper staging. Some patients who might benefit fram adjuvant therapy are misclassified as node-negative due to incomplete sampling of lymph nodes. J Clin Oncol 19:157-163. (C) 2001 by American Society of Clinical Oncology.
引用
收藏
页码:157 / 163
页数:7
相关论文
共 28 条
  • [21] Pocard M, 1998, DIS COLON RECTUM, V41, P839, DOI 10.1007/BF02235362
  • [22] LOCAL RECURRENCE OF RECTAL ADENOCARCINOMA DUE TO INADEQUATE SURGICAL RESECTION - HISTOPATHOLOGICAL STUDY OF LATERAL TUMOR SPREAD AND SURGICAL EXCISION
    QUIRKE, P
    DIXON, MF
    DURDEY, P
    WILLIAMS, NS
    [J]. LANCET, 1986, 2 (8514) : 996 - 999
  • [23] QUIRKE P, 1992, SURG ONCOL CLIN N AM, V3, P1
  • [24] Ratto C, 1999, DIS COLON RECTUM, V42, P143, DOI 10.1007/BF02237119
  • [25] DETECTION OF LYMPH-NODE METASTASES IN COLORECTAL-CARCINOMA BEFORE AND AFTER FAT CLEARANCE
    SCOTT, KWM
    GRACE, RH
    [J]. BRITISH JOURNAL OF SURGERY, 1989, 76 (11) : 1165 - 1167
  • [26] Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114
    Tepper, JE
    OConnell, MJ
    Petroni, GR
    Hollis, D
    Cooke, E
    Benson, AB
    Cummings, B
    Gunderson, LL
    Macdonald, JS
    Martenson, JA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 2030 - 2039
  • [27] Prognostic factors in stage T3NO rectal cancer - Do all patients require postoperative pelvic irradiation and chemotherapy?
    Willett, CG
    Badizadegan, K
    Ancukiewicz, M
    Shellito, PC
    [J]. DISEASES OF THE COLON & RECTUM, 1999, 42 (02) : 167 - 173
  • [28] Number of nodes examined and staging accuracy in colorectal carcinoma
    Wong, JH
    Severino, R
    Honnebier, MB
    Tom, P
    Namiki, TS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2896 - 2900